<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 18 May 2021 19:23:22 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>罗氏全球首个加速器在上海启动，引领中国本土医疗行业创新</title><link>https://mp.weixin.qq.com/s/0-rSS9tFtOPGcQ_nNd_l2A</link><description></description><content:encoded><![CDATA[罗氏全球首个加速器在上海启动，引领中国本土医疗行业创新]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>信达生物PD1单抗美国上市申请获受理</title><link>https://mp.weixin.qq.com/s/4ADsux_IJBMm_YhE-q4f2Q</link><description></description><content:encoded><![CDATA[信达生物PD1单抗美国上市申请获受理]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>有望成为首个上市的白癜风治疗药物，芦可替尼乳膏III期研究成功</title><link>https://mp.weixin.qq.com/s/XkcDEnWX19kHZHJ1VFdzEQ</link><description></description><content:encoded><![CDATA[有望成为首个上市的白癜风治疗药物，芦可替尼乳膏III期研究成功]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>新一代HER2-ADC获CDE拟突破性疗法</title><link>https://mp.weixin.qq.com/s/0xv_A_c3hKxoprlKPRHruQ</link><description></description><content:encoded><![CDATA[新一代HER2-ADC获CDE拟突破性疗法]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>康方生物CD47单抗骨髓增生异常综合症I/II期研究申请获许可</title><link>https://mp.weixin.qq.com/s/7UHVxBGTriRvz1tVEjzBGw</link><description></description><content:encoded><![CDATA[康方生物CD47单抗骨髓增生异常综合症I/II期研究申请获许可]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>诺诚健华自研新型TYK2抑制剂ICP-332获批临床</title><link>https://mp.weixin.qq.com/s/XkAZGQm7ydaqS77SoH-BTQ</link><description></description><content:encoded><![CDATA[诺诚健华自研新型TYK2抑制剂ICP-332获批临床]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>克服BTK耐药，默沙东BTK-C481S抑制剂申报临床</title><link>https://mp.weixin.qq.com/s/9o0DAnZYJeIkeHD5zwAlag</link><description></description><content:encoded><![CDATA[克服BTK耐药，默沙东BTK-C481S抑制剂申报临床]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>首个「阿昔替尼」仿制药即将获批上市</title><link>https://mp.weixin.qq.com/s/RXfgNmogKeYUYTJXxXNSbw</link><description></description><content:encoded><![CDATA[首个「阿昔替尼」仿制药即将获批上市]]></content:encoded><pubDate>Mon, 17 May 2021 18:05:40 +0800</pubDate></item><item><title>首个选择性PI3Kδ抑制剂申报上市，恒瑞/璎黎药业联合开发</title><link>https://mp.weixin.qq.com/s/P1BohCDAizJUzFOPdz5eyA</link><description></description><content:encoded><![CDATA[首个选择性PI3Kδ抑制剂申报上市，恒瑞/璎黎药业联合开发]]></content:encoded><pubDate>Mon, 17 May 2021 18:05:40 +0800</pubDate></item><item><title>百济神州帕米帕利定价公开：2.1万元/月</title><link>https://mp.weixin.qq.com/s/ojl_pt7LFtFHX2IqCAGjVg</link><description></description><content:encoded><![CDATA[百济神州帕米帕利定价公开：2.1万元/月]]></content:encoded><pubDate>Mon, 17 May 2021 18:05:40 +0800</pubDate></item><item><title>补体C3抑制剂获FDA批准上市，挑战40亿美元重磅药物依库珠单抗</title><link>https://mp.weixin.qq.com/s/QSa3Jc7V9ajybxjtLWx0oQ</link><description></description><content:encoded><![CDATA[补体C3抑制剂获FDA批准上市，挑战40亿美元重磅药物依库珠单抗]]></content:encoded><pubDate>Sat, 15 May 2021 11:57:19 +0800</pubDate></item><item><title>Biogen 眼科疾病基因疗法 II/III 期临床研究失败</title><link>https://mp.weixin.qq.com/s/HzwAZW2K7Sw2BuuxXefHYg</link><description></description><content:encoded><![CDATA[Biogen 眼科疾病基因疗法 II/III 期临床研究失败]]></content:encoded><pubDate>Sat, 15 May 2021 11:57:19 +0800</pubDate></item><item><title>今日，19款仿制药过评，重磅品种碘克沙醇新增过评企业，1款新药获批上市</title><link>https://mp.weixin.qq.com/s/pMXYO56UYdbNNsDvBeUr4A</link><description></description><content:encoded><![CDATA[今日，19款仿制药过评，重磅品种碘克沙醇新增过评企业，1款新药获批上市]]></content:encoded><pubDate>Fri, 14 May 2021 17:57:09 +0800</pubDate></item><item><title>重磅！高瓴30亿港元入股金斯瑞，股价大涨！</title><link>https://mp.weixin.qq.com/s/iNuW3G1tTH82jKfbYCuL2A</link><description></description><content:encoded><![CDATA[重磅！高瓴30亿港元入股金斯瑞，股价大涨！]]></content:encoded><pubDate>Fri, 14 May 2021 17:57:09 +0800</pubDate></item><item><title>默沙东Keytruda早期三阴性乳腺癌新辅助/辅助III期研究达到EFS主要终点</title><link>https://mp.weixin.qq.com/s/xiZ7U-hyUIDNLuuQDtjt7g</link><description></description><content:encoded><![CDATA[默沙东Keytruda早期三阴性乳腺癌新辅助/辅助III期研究达到EFS主要终点]]></content:encoded><pubDate>Fri, 14 May 2021 17:57:09 +0800</pubDate></item><item><title>500→620！国采加速度，省级集采目录再扩充</title><link>https://mp.weixin.qq.com/s/tUKNzU1HFgSTWQMlDnanqA</link><description></description><content:encoded><![CDATA[500→620！国采加速度，省级集采目录再扩充]]></content:encoded><pubDate>Fri, 14 May 2021 17:57:09 +0800</pubDate></item><item><title>阿斯利康GLP-1/GCGR双重激动剂申报临床</title><link>https://mp.weixin.qq.com/s/c_65pQuUHXmmBPCn7rtFEA</link><description></description><content:encoded><![CDATA[阿斯利康GLP-1/GCGR双重激动剂申报临床]]></content:encoded><pubDate>Fri, 14 May 2021 17:57:09 +0800</pubDate></item><item><title>BMS递交LAG-3+PD-1单抗复方制剂临床申请</title><link>https://mp.weixin.qq.com/s/9feFRlqLb5UyCQuLT-SLBA</link><description></description><content:encoded><![CDATA[BMS递交LAG-3+PD-1单抗复方制剂临床申请]]></content:encoded><pubDate>Fri, 14 May 2021 17:57:09 +0800</pubDate></item><item><title>Nature：中国上市肿瘤新药的加速路径分析</title><link>https://mp.weixin.qq.com/s/XSGUnbLWyWLRUZCTS783vQ</link><description></description><content:encoded><![CDATA[Nature：中国上市肿瘤新药的加速路径分析]]></content:encoded><pubDate>Thu, 13 May 2021 18:16:41 +0800</pubDate></item><item><title>治疗儿童近视！首款角膜塑形隐形眼镜获FDA批准上市</title><link>https://mp.weixin.qq.com/s/oOiaKIxHGPP_Pc5ffn3CdQ</link><description></description><content:encoded><![CDATA[治疗儿童近视！首款角膜塑形隐形眼镜获FDA批准上市]]></content:encoded><pubDate>Thu, 13 May 2021 18:16:41 +0800</pubDate></item></channel></rss>